Breaking News Instant updates and real-time market news.

SSNLF

Samsung

, AAPL

Apple

$155.39

1.91 (1.24%)

07:32
10/06/17
10/06
07:32
10/06/17
07:32

DOJ recommends Supreme Court deny Samsung-Apple review, CNET reports

The U.S. Department of Justice has recommended that the Supreme Court deny Samsung's (SSNLF) request to review a 2014 ruling that awarded Apple (AAPL) $120M for patent infringement, CNET reports. Samsung, which has been embroiled in a legal battle with Apple since 2012, won a victory in the Supreme Court last year over how much money could be owed for the patent infringement. Reference Link

SSNLF

Samsung

AAPL

Apple

$155.39

1.91 (1.24%)

  • 08

    Oct

  • 22

    Oct

SSNLF Samsung

08/22/17
OPCO
08/22/17
NO CHANGE
Target $35
OPCO
Underperform
Synaptics price target lowered to $35 from $45 at Oppenheimer
Oppenheimer analyst Andrew Uerkwitz lowered his price target for Synaptics (SYNA) to $35 from $45, citing his bearish outlook on the company's fingerprint and DDIC business. The analyst's model implies "significant" fingerprint revenue loss from Samsung (SSNLF) and ongoing decline of DDIC revenues from Apple (AAPL). Meanwhile, Uerkwitz believes its new products such as optical fingerprint sensor and OLED DDIC are unlikely to offset the decline until after FY19. He reiterates an Underperform rating on Synaptics' shares.
09/13/17
STFL
09/13/17
NO CHANGE
STFL
Buy
Foldable smartphones another potential catalyst for Coherent, says Stifel
Stifel analyst Patrick Newton noted that AP reported yesterday that the President of Samsung's (SSNLF) mobile business said the company could release its anticipated foldable smartphone as soon as next year. Such a potential launch, and likely broader adoption of the technology by peers, is a potential long-term catalyst for Coherent (COHR) and other such equipment suppliers whose revenues are linearly correlated with total screen area, he tells investors. Also, higher resolution OLED displays, like the one confirmed yesterday for Apple's (AAPL) iPhone X, are a positive for Coherent's future recurring revenue from laser discharge units, added Newton, who keeps a Buy rating on Coherent shares.
09/14/17
KEYB
09/14/17
NO CHANGE
KEYB
Lack of Band 71 inclusion a near-term negative for T-Mobile, says KeyBanc
KeyBanc analyst Brandon Nispel says that the lack of inclusion of band 71, or 600 MHz spectrum, in iconic device launches from Samsung (SSNLF) and Apple (AAPL) is a clear negative for T-Mobile (TMUS). T-Mobile spent $8B to purchase this spectrum and will spend more capital going forward to build it out, without having the ability to put it to use for at least another year, he notes. Nispel believes investors are likely to view this as negative, and it could cause some weakness to shares.
09/29/17
CHLM
09/29/17
NO CHANGE
Target $48
CHLM
Buy
Craig-Hallum says Xperi suit against Samsung disappointing, but likely priced in
Craig-Hallum analyst Richard Shannon called Xperi's (XPER) lawsuit against Samsung (SSNLF) "disappointing" and said hoping Samsung settles like it did with Broadcom (AVGO) is "wishful thinking." He removed Samsung revenues from his model for Xperi through 2018, but also said he thinks most of Samsung worries are baked into the stock at current levels. Shannon maintains his Buy rating and $48 price target on Xperi, which he still sees being in a strong position.
AAPL Apple
$155.39

1.91 (1.24%)

09/28/17
STFL
09/28/17
NO CHANGE
Target $30
STFL
Hold
Jabil Circuit near-term 'hazy' due to Apple production ramp timing, says Stifel
Stifel analyst Matthew Sheerin attributes Jabil Circuit's "particularly wide" guidance for the new quarter to uncertainty around timing for production runs of Apple's (AAPL) iPhone X. The company's DMS segment margins missed expectations due to manufacturing hiccups related to production ramps for Apple casings and frames for the iPhones, he believes, adding that Jabil said those issues lingered into September but have since been resolved. Sheerin keeps a Hold rating and $30 price target on Jabil shares.
09/28/17
NEED
09/28/17
NO CHANGE
NEED
Jabil Circuit should be bought on weakness, says Needham
Needham analyst Sean Hannan says that Jabil (JBL) reported "fairly healthy" Q4 results. The analyst believes that the company is making progress in its effort to diversify its business away from Apple (AAPL), while its product mix and "general execution" are improving. He recommends buying the stock on weakness.
10/02/17
RBCM
10/02/17
NO CHANGE
RBCM
Survey shows 'strong' demand for iPhone X, says RBC Capital
After RBC Capital conducted a survey of over 4,000 people, Amit Daryanani, an analyst at the firm, says that 28% of respondents are "interested" in buying the iPhone X, while 64% of respondents are interested in buying one of the new iPhones, down from 71% a year ago. The analyst says that the data indicates that demand for iPhone x is "strong," while the survey "suggests there could be stability in the iPhone replacement cycle" and switching from Android could increase. He keeps a $180 price target and an Outperform rating on the shares.
10/04/17
BARD
10/04/17
NO CHANGE
Target $175
BARD
Outperform
Apple survey findings positive for iPhone and watch, says Baird
Baird analyst William Power said his latest Apple survey suggests strong interest for both iPhone 8 and X, with a higher skewing toward the newer models than in years past. He believes that should boost the average selling price, so he raised his estimates modestly, but remains below consensus. Power reiterated his Outperform rating and raised his price target to $175 from $172 on Apple shares.

TODAY'S FREE FLY STORIES

07:46
02/22/18
02/22
07:46
02/22/18
07:46
Conference/Events
FDA to co-host a workshop »

The FDA, American…

MLNX

Mellanox

07:44
02/22/18
02/22
07:44
02/22/18
07:44
Recommendations
Mellanox analyst commentary  »

Mellanox price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

RDHL

RedHill Biopharma

$6.26

0.05 (0.81%)

07:44
02/22/18
02/22
07:44
02/22/18
07:44
Earnings
RedHill Biopharma reports Q4 EPS (26c), consensus (60c) »

Reports Q4 revenue $2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

07:43
02/22/18
02/22
07:43
02/22/18
07:43
Conference/Events
JPMorgan to hold a conference »

Korea Conference will be…

HSC

Harsco

$16.75

0.45 (2.76%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Earnings
Breaking Earnings news story on Harsco »

Harsco sees FY18 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Conference/Events
Deutsche Bank to hold a conference »

Indonesia Corporate Days…

ROKU

Roku

$51.10

-0.08 (-0.16%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 21

    Mar

HSC

Harsco

$16.75

0.45 (2.76%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Earnings
Breaking Earnings news story on Harsco »

Harsco sees Q1 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

AKBA

Akebia

$14.31

0.69 (5.07%)

, CRSP

Crispr Therapeutics

$41.16

-0.45 (-1.08%)

07:41
02/22/18
02/22
07:41
02/22/18
07:41
Conference/Events
RBC Capital to hold a conference »

Global Healthcare…

AKBA

Akebia

$14.31

0.69 (5.07%)

CRSP

Crispr Therapeutics

$41.16

-0.45 (-1.08%)

RDUS

Radius Health

$37.71

-0.51 (-1.33%)

TYME

Tyme Technologies

$3.37

-0.06 (-1.75%)

HCA

HCA Healthcare

$100.35

-0.65 (-0.64%)

ARAY

Accuray

MDRX

Allscripts

$13.57

0.335 (2.53%)

ABEO

Abeona Therapeutics

$11.70

0.1 (0.86%)

SGEN

Seattle Genetics

$54.11

-0.05 (-0.09%)

INSY

Insys Therapeutics

$7.93

0.34 (4.48%)

SPPI

Spectrum

$20.51

0.21 (1.03%)

SPH

Suburban Propane

$24.10

-0.2 (-0.82%)

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

DEPO

Depomed

$7.46

0.07 (0.95%)

KTWO

K2M Group

$19.09

-0.01 (-0.05%)

INOV

Inovalon

$11.68

-1.025 (-8.07%)

IMMU

Immunomedics

$16.38

0.16 (0.99%)

OVID

Ovid Therapeutics

$6.83

-0.2 (-2.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 11

    Mar

  • 14

    Mar

  • 01

    May

  • 03

    May

  • 22

    Feb

HSC

Harsco

$16.75

0.45 (2.76%)

07:40
02/22/18
02/22
07:40
02/22/18
07:40
Earnings
Harsco reports Q4 EPS ex-items 20c, consensus 14c »

Reports Q4 revenue $455M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

WPC

W.P. Carey

$59.53

-0.73 (-1.21%)

07:40
02/22/18
02/22
07:40
02/22/18
07:40
Hot Stocks
W.P. Carey enters into 18-year triple net lease with Astellas Institute »

W. P. Carey has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

07:40
02/22/18
02/22
07:40
02/22/18
07:40
General news
Fed's Quarles anticipates further gradual tightening »

Fed's Quarles…

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:39
02/22/18
02/22
07:39
02/22/18
07:39
Earnings
Gibraltar Industries sees FY18 adjusted EPS $1.96-$2.08, consensus $1.81 »

Gibraltar is providing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$109.06

-1.92 (-1.73%)

07:39
02/22/18
02/22
07:39
02/22/18
07:39
Recommendations
Chevron analyst commentary  »

Chevron weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRC

Brady

$38.05

0.1 (0.26%)

07:38
02/22/18
02/22
07:38
02/22/18
07:38
Earnings
Brady reports Q2 EPS 8c, may not be compared to consensus 44c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:38
02/22/18
02/22
07:38
02/22/18
07:38
Earnings
Gibraltar Industries sees Q1 adjusted EPS 23c-28c, one est. 30c »

For Q1, the company is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCN

Welltower

$53.99

-0.81 (-1.48%)

07:37
02/22/18
02/22
07:37
02/22/18
07:37
Earnings
Welltower sees 2018 normalized FFO $3.95-$4.05, consensus $4.20 »

Expects average blended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ARWR

Arrowhead

$5.54

-0.11 (-1.95%)

07:36
02/22/18
02/22
07:36
02/22/18
07:36
Hot Stocks
Arrowhead receives regulatory clearance to begin Phase 1 study of ARO-AAT »

Arrowhead Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AABA

Altaba

$75.11

0.52 (0.70%)

07:36
02/22/18
02/22
07:36
02/22/18
07:36
Recommendations
Altaba analyst commentary  »

Altaba price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

HCN

Welltower

$53.99

-0.81 (-1.48%)

07:36
02/22/18
02/22
07:36
02/22/18
07:36
Earnings
Welltower reports Q4 normalized FFO $1.02, consensus $1.04 »

Reports Q4 revenue $1.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:35
02/22/18
02/22
07:35
02/22/18
07:35
Earnings
Gibraltar Industries reports Q4 adjusted EPS 41c, consensus 34c »

Reports Q4 revenue $258M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGEN

Repligen

$32.40

0.64 (2.02%)

07:35
02/22/18
02/22
07:35
02/22/18
07:35
Earnings
Repligen sees FY18 adjusted EPS 68c-72c, consensus 72c »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SRCL

Stericycle

$74.91

-0.31 (-0.41%)

07:35
02/22/18
02/22
07:35
02/22/18
07:35
Recommendations
Stericycle analyst commentary  »

Stericycle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAWS

Lawson Products

$23.80

0.3 (1.28%)

07:35
02/22/18
02/22
07:35
02/22/18
07:35
Earnings
Lawson reports Q4 EPS $2.21 including items, may not compare to two est. 16c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

C

Citi

$77.00

0.54 (0.71%)

, WFC

Wells Fargo

$59.73

-0.22 (-0.37%)

07:35
02/22/18
02/22
07:35
02/22/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

C

Citi

$77.00

0.54 (0.71%)

WFC

Wells Fargo

$59.73

-0.22 (-0.37%)

GM

General Motors

$40.56

-0.21 (-0.52%)

P

Pandora

$4.87

-0.46 (-8.63%)

ILG

ILG

$32.31

0.12 (0.37%)

BHGE

Baker Hughes

$26.76

0.32 (1.21%)

SLCA

U.S. Silica

$25.15

-5.6 (-18.21%)

RF

Regions Financial

$19.62

0.22 (1.13%)

SPB

Spectrum Brands

$100.87

-1.03 (-1.01%)

MNST

Monster Beverage

$65.02

0.42 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 15

    Mar

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.